R. J. Moots

650 total citations
17 papers, 461 citations indexed

About

R. J. Moots is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, R. J. Moots has authored 17 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology. Recurrent topics in R. J. Moots's work include Systemic Lupus Erythematosus Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). R. J. Moots is often cited by papers focused on Systemic Lupus Erythematosus Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). R. J. Moots collaborates with scholars based in United Kingdom, France and Portugal. R. J. Moots's co-authors include Helen L. Wright, Steven W. Edwards, R C Bucknall, P. Prouse, J M Gumpel, Jeremy Hayllar, Andrew J. Macpherson, Ingvar Bjarnason, David L. Scott and I. S. Menzies and has published in prestigious journals such as Gut, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

R. J. Moots

17 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. J. Moots United Kingdom	7	163	120	111	89	64	17	461
Ana Sáiz Spain	11	50 0.3×	98 0.8×	72 0.6×	109 1.2×	80 1.3×	34	435
Yasunori Matsuki Japan	15	230 1.4×	221 1.8×	45 0.4×	122 1.4×	40 0.6×	40	662
Anita W.L. Tsang Hong Kong	14	41 0.3×	155 1.3×	81 0.7×	171 1.9×	85 1.3×	16	641
Samuel Bitoun France	9	85 0.5×	76 0.6×	45 0.4×	90 1.0×	24 0.4×	20	371
Jennifer Hawkins United States	7	82 0.5×	121 1.0×	75 0.7×	144 1.6×	25 0.4×	8	525
Hironaga Kuwahara Japan	14	52 0.3×	141 1.2×	191 1.7×	132 1.5×	18 0.3×	21	570
T Okanoue Japan	6	113 0.7×	67 0.6×	55 0.5×	67 0.8×	38 0.6×	10	534
Peter Sallstig Switzerland	8	252 1.5×	100 0.8×	241 2.2×	313 3.5×	23 0.4×	16	773
Ting Jiang China	13	135 0.8×	97 0.8×	47 0.4×	195 2.2×	59 0.9×	30	491
P. Kaklamanis Greece	12	192 1.2×	39 0.3×	73 0.7×	47 0.5×	38 0.6×	28	489

Countries citing papers authored by R. J. Moots

Since Specialization

Citations

This map shows the geographic impact of R. J. Moots's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. J. Moots with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. J. Moots more than expected).

Fields of papers citing papers by R. J. Moots

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. J. Moots. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. J. Moots. The network helps show where R. J. Moots may publish in the future.

Co-authorship network of co-authors of R. J. Moots

This figure shows the co-authorship network connecting the top 25 collaborators of R. J. Moots. A scholar is included among the top collaborators of R. J. Moots based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. J. Moots. R. J. Moots is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Dörner, Thomas, Simon Bowman, Robert J. Fox, et al.. (2021). POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. Annals of the Rheumatic Diseases. 80. 593–594. 1 indexed citations

Mitchell, Tamara, R. J. Moots, & Helen L. Wright. (2017). Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production. Clinical & Experimental Immunology. 189(2). 250–258. 43 indexed citations

Chadwick, L, et al.. (2017). AB0573 Autologous stem cell transplantation in the management of refractory behÇet's syndrome: a case series from a single centre of excellence. Annals of the Rheumatic Diseases. 76. 1251–1251. 1 indexed citations

Moots, R. J., et al.. (2015). DMARD use in Rheumatoid Arthritis: Can we Predict Treatment Response?. 2(3). 50–58. 1 indexed citations

Moots, R. J., et al.. (2012). The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Lara D. Veeken. 51(12). 2252–2261. 43 indexed citations

Wright, Helen L., R C Bucknall, R. J. Moots, & Steven W. Edwards. (2011). Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Lara D. Veeken. 51(3). 451–459. 86 indexed citations

Barnes, T. Cunliffe, David G. Spiller, Marina Anderson, Steven W. Edwards, & R. J. Moots. (2010). Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis?. Annals of the Rheumatic Diseases. 70(2). 366–372. 57 indexed citations

Moots, R. J., et al.. (2005). Congenital heart block associated with undiagnosed maternal Primary Sjögren's Syndrome – a case report and discussion. Oral Diseases. 11(3). 190–192. 3 indexed citations

Moots, R. J., et al.. (2001). Late onset Raynaud's phenomenon, hypertension, deteriorating renal function, and a fit in a middle aged woman. Postgraduate Medical Journal. 77(914). e10–e10. 1 indexed citations

10.

Sigthorsson, G, Jeremy Hayllar, I. S. Menzies, et al.. (1998). Intestinal permeability and inflammation in patients on NSAIDs. Gut. 43(4). 506–511. 149 indexed citations

11.

Moots, R. J.. (1998). A fistful of T cells. Lara D. Veeken. 37(6). 602–611. 8 indexed citations

12.

Moots, R. J., et al.. (1994). 115. Intestinal permeability in arthritis assessed by 51Cr-EDTA. Nuclear Medicine Communications. 15(4). 257–257. 1 indexed citations

13.

Moots, R. J., Stephen P. Young, Jack L. Strominger, et al.. (1993). INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE. Lara D. Veeken. 32. 24–24. 2 indexed citations

14.

Luqmani, Raashid, R. J. Moots, Paul Emery, P. A. Bacon, & Dwomoa Adu. (1993). Cyclophosphamide and systemic vasculitis. QJM. 1 indexed citations

15.

Moss, Paul, et al.. (1991). EXTENSIVE CONSERVATION OF ALPHA-CHAIN AND BETA-CHAIN OF THE HUMAN T-CELL ANTIGEN RECEPTOR RECOGNIZING HLA-A2 AND INFLUENZA-A MATRIX PEPTIDE. UCL Discovery (University College London). 2 indexed citations

16.

Moots, R. J., P. Prouse, & J M Gumpel. (1988). Near fatal eosinophilic gastroenteritis responding to oral sodium chromoglycate.. Gut. 29(9). 1282–1285. 57 indexed citations

17.

Moots, R. J. & Avik Banerjee. (1988). Drug points: Exfoliative dermatitis after amiodarone treatment. BMJ. 296(6632). 1332–1333. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact